Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REGIME: A Randomised Controlled Trial of Prolonged Treatment With Darbepoetin Alpha, With or Without Recombinant Human Granulocyte Colony Stimulating Factor, Versus Best Supportive Care in Patients With Low-risk Myelodysplastic Syndromes (MDS).

NCT01196715 is registered in ClinicalTrials.gov with Barts & The London NHS Trust as lead sponsor.

NCT NCT01196715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01196715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REGIME: A Randomised Controlled Trial of Prolonged Treatment With Darbepoetin Alpha, With or Without Recombinant Human Granulocyte Colony Stimulating Factor, Versus Best Supportive Care in Patients With Low-risk Myelodysplastic Syndromes (MDS).
Lead sponsor
Barts & The London NHS Trust
Phase
Phase 3
Overall status
Completed
Start date
November 1, 2010
Completion date
October 31, 2015
Enrollment
360 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome